Purdue Research Foundation

Arizona Board of Regents, a Body Corporate

Symic IP, LLC

University of California

Moerae Matrix, Inc.

Symic Biomedical, Inc.

Komalavilas, Padmini

Lokesh, Joshi

Seal, Brandon

Brophy, Colleen

Panitch, Alyssa

Alyssa Panitch

Brandon Seal

John Eric Paderi

Padmini Komalavilas

Colleen Brophy

Katherine Allison Stuart

Shaili Sharma

Kinam Park

Brian C Ward

Steve Higbee

Lokesh Joshi

Elizabeth Furnish

Brian P Ward

Catherine Parmiter

Nelda Marie Vazquez-Portalatin

James McMasters

Rush L Bartlett

Jamie L Brugnano

Rebecca Scott

Kit S Lam

Ruiwu Liu

Aijun Wang

Jenny B Lin

Emily Michelle Misnick

Dake Hao

Jonathan C Bernhard

Andrew Woolley

Nnadozie Onunkwo

Kevin Otto

Catherin Dreiza

Coleen Brophy

James Wodicka

Joshi Lokesh

Katherine Stuart

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair

The invention relates to peptide conjugates that can bind to endothelial cells, and that are useful for reducing the incidence and severity of endothelial dysfunction in mammals.

Selectin and ICAM/VCAM peptide ligand conjugates

Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.

Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction

This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.

Collagen-binding synthetic peptidoglycans, preparation, and methods of use

The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states.

Compositions and methods for delivery of kinase inhibiting peptides

The described invention provides compositions comprising at least one peptide of formula I for enhancing neurite outgrowth, neuroprotection, and nerve regeneration, and methods of use thereof.

MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration

This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use.

Extracellular matrix-binding synthetic peptidoglycans

The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.

Polypeptide inhibitors of HSP27 kinase and uses therfor

Polypeptide inhibitors of HSP27 kinase and uses therefor

The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.

Kinase inhibitors and uses thereof

The described invention provides kinase inhibiting compositions containing a therapeutic amount of a therapeutic inhibitor peptide that inhibits at least one kinase enzyme, methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression using the kinase inhibiting compositions.

Cell-permeant peptide-based inhibitor of kinases

This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.

Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use

Growing community of inventors

West Lafayette, IN, United States of America

Alyssa Panitch